Promising approach for multiple tumors (even if in its early stage).
RPT04402 is a first-in-class molecular glue that selectively reactivates PP2A, a tumor suppressor enzyme crucial for regulating cell growth.
By restoring PP2A activity, this therapy suppresses oncogenic pathways, offering a novel approach to address treatment-resistant prostate cancer.
Preclinical studies show its potential to slow or reverse tumor progression, making it a promising strategy for advanced cases. An Investigational New Drug (IND) application is expected by the end of 2025, paving the way for clinical trials.
Seminal Vesicle Invasion & Senescent tumor cells.
Doxycycline